Drug Profile
Research programme: inherited muscular disorder therapeutics - Travere Therapeutics
Alternative Names: RE-001; RE-002; RE-003Latest Information Update: 02 Jun 2021
Price :
$50
*
At a glance
- Originator Retrophin
- Developer National Center for Advancing Translational Sciences; Travere Therapeutics
- Class Recombinant fusion proteins; Small molecules
- Mechanism of Action Dystrophin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inborn genetic disorders
- Discontinued Congenital structural myopathies; Duchenne muscular dystrophy; Spinal muscular atrophy
Most Recent Events
- 17 May 2021 Preclinical trials in Inborn genetic disorders in USA (unspecified route)
- 16 Nov 2020 Retrophin is now called Travere Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral)